Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Momenta’s Decision To Ditch Abatacept Makes Orencia Dispute Moot

Executive Summary

Abandoning development of a biosimilar removes any right to challenge patents protecting the reference biologic, the US Court of Appeals has stated in dismissing Momenta’s appeal over abatacept.

You may also be interested in...



Momenta plans exit of Mylan biosimilars

Momenta Pharmaceuticals has “initiated discussions” with partner Mylan to exit its participation in the development of five biosimilar programs, including the firms’ M834 biosimilar Orencia (abatacept) candidate, after completing a strategic review “aimed at reducing costs of biosimilar development” and focusing its resources on its pipeline of novel drug candidates.

Pressure Mounts For German Tender Reforms

Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.

Teva Leapfrogs Mylan And Sandoz On Linaclotide

A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB140072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel